Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Malawi

NCT01326754 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT01326754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01326754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Malawi
Lead sponsor
Centers for Disease Control and Prevention
Phase
Not applicable
Overall status
Completed
Start date
August 31, 2011
Completion date
June 30, 2012
Enrollment
498 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, falciparum